Zentalis plots DENALI Part 2 readout in 1H 2027 as cash thins
Zentalis Pharmaceuticals has reported its second-quarter 2026 financial results alongside a cluster of clinical and regulatory updates for azenosertib, its investigational WEE1 inhibitor in platinum-resistant ovarian cancer (PROC). The San Diego company said it remains on track to deliver a topline readout from the DENALI Part 2 trial in the first half of 2027, with enrolment complete in Parts 2a and 2b and Part 2c actively enrolling.
The central regulatory development is confirmation that a Type D meeting with the FDA produced no objections to the selected monotherapy dose of 400 mg once daily on a 5-days-on, 2-days-off schedule in Cyclin E1-positive PROC patients. The agency also acknowledged that the integrated DENALI Part 2 dataset, spanning all three cohorts, has the potential to support an accelerated approval pathway, though it reserved judgement on whether that bar will ultimately be met, citing dependence on the strength of the data and the competitive landscape at the time of any regulatory action.
Clinical programme
The DENALI trial is structured to give Zentalis two bites at the regulatory apple. Part 2, a registration-intended Phase 2 study, is designed to underpin an accelerated approval application, while ASPENOVA, a Phase 3 confirmatory trial that dosed its first patient in May 2026, is intended to support conversion to full approval and to enable filings in major markets outside the United States. ASPENOVA is expected to enrol approximately 420 patients and uses progression-free survival as its primary endpoint, with overall survival and overall response rate as key secondary measures.
The MUIR Phase 1b combination study added supportive data at the American Society of Clinical Oncology meeting in 2026. Results from Part 1 showed combinability of azenosertib with paclitaxel in an all-comer PROC setting, and Part 2 is now enrolling patients receiving azenosertib plus bevacizumab as a second-line maintenance regimen in platinum-sensitive disease. Zentalis has also had two abstracts accepted for the European Society for Medical Oncology annual meeting later in 2026, including an oral presentation of overall survival data from DENALI Part 1b.
Financial position and market context
Zentalis ended June 2026 with $174.6 million in cash, cash equivalents and marketable securities, down from $245.9 million at the end of 2025. The company said this is sufficient to fund operations into late 2027, which, if the DENALI readout arrives on schedule in the first half of that year, would leave limited financial headroom between data disclosure and any potential approval or fundraising event. Research and development expenses rose to $35.2 million in the quarter, up from $27.6 million in the same period a year earlier, driven partly by a $7.0 million milestone payment to Recurium IP Holdings triggered by the commencement of ASPENOVA.
The WEE1 inhibitor space remains comparatively uncrowded at the late-clinical stage, but ovarian cancer broadly is a fiercely competitive oncology segment. PARP inhibitors from AstraZeneca, GSK and Pfizer dominate the maintenance setting, while newer antibody-drug conjugates are advancing in later lines of therapy. Zentalis is seeking to differentiate azenosertib through its Cyclin E1 biomarker selection strategy, which the company estimates covers approximately half of PROC patients, a population it characterises as having no currently approved biomarker-specific option. The degree to which that differentiation will satisfy an FDA looking at the full treatment landscape at the time of a potential filing remains the pivotal unknown ahead of the 2027 readout.
Chief executive Julie Eastland said the company was "as confident as ever" that azenosertib could serve as an important oral, non-chemotherapy option for this patient group, and pointed to expansion opportunities in platinum-sensitive ovarian cancer and other tumour types as longer-term pipeline optionality.